Analysts See Big Upside in Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a consensus Buy with all seven analysts covering it assigning it a Buy or equivalent rating. With a median price of $35, the stock has an upside potential of 48.75% from its current price.

Earlier on November 26, Chief Commercial Officer of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), Jeffrey Del Carmen, offloaded 10,983 shares of common stock, valued at approximately $256,244. According to the latest Form 4 filing with the Securities and Exchange Commission, Del Carmen now owns 3,962 shares of the company’s stock.

During the company’s presentation at the Jefferies London Healthcare Conference 2025 on November 17, management highlighted plans to advance education in the oncology space for LEMS. Driving further interest, Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) disclosed its efforts to accelerate organic growth by targeting patients at various stages of the diagnostic journey. Despite competition in the epilepsy market, the company remains committed to patient support and strategic acquisitions.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) is a Florida-based commercial-stage biopharmaceutical company focused on treatments for people living with life-threatening diseases. Founded in 2002, the company offers Firdapse, Fycompa, Ruzurgi, and AGAMREE.

While we acknowledge the potential of CPRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.